keyword
MENU ▼
Read by QxMD icon Read
search

SLE Nephritis

keyword
https://www.readbyqxmd.com/read/28217919/serious-infection-rates-among-children-with-systemic-lupus-erythematosus-enrolled-in-medicaid
#1
Linda T Hiraki, Candace H Feldman, Francisco M Marty, Wolfgang C Winkelmayer, Hongshu Guan, Karen H Costenbader
OBJECTIVE: To investigate the nationwide prevalence and incidence of serious infections among children with systemic lupus erythematosus (SLE) enrolled in Medicaid, the U.S. health insurance program for low-income patients. METHODS: From Medicaid claims (2000-2006) we identified children 5 to <18 years old with SLE (≥3 ICD-9 codes of 710.0, each >30 days apart) and lupus nephritis (LN; ≥2 ICD-9 codes for kidney disease on/after SLE codes). From hospital discharge diagnoses, we identified infection subtypes (bacterial, fungal, viral)...
February 19, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28216896/therapeutic-effect-of-dendrobium-candidum-on-lupus-nephritis-in-mice
#2
Qiang Wang, Peng Sun, Rui Wang, Xin Zhao
CONTEXT: Dendrobium candidum (D. candimum) widely is a functional drug. The curative effect of D. candidum on lupus nephritis has been studied in vivo. MATERIALS AND METHOD: The DBA/2 and B6D2F1 mice were used for this in vivo experiment. The 50% effective dose (ED50) was used to check the effective concentration for this study. Then the SCr, BUN, TC, TG, IL-6, IL-12, TNF-α, and IFN-γ levels were determined by kits. The output of urine protein was determined by means of Coomassie Brilliant Blue, and the auto-antibody dsDNA was determined with titer plate technology and indirect immunofluorescence...
January 2017: Pharmacognosy Magazine
https://www.readbyqxmd.com/read/28213738/cytomegalovirus-infection-in-patients-with-lupus-nephritis-clinical-and-laboratory-features-and-therapeutic-considerations
#3
Lei Zhang, Jianling Tao, Yubing Wen, Li Li, Xueyi Wu, Xuewang Li, Xuemei Li
To better clarify the clinical features and therapeutic strategy of CMV infection in lupus nephritis patients, we retrospectively surveyed a total of 40 lupus nephritis patients, who had been hospitalized and underwent renal biopsy and diagnosed as having CMV infection during their hospitalization at our institution within the last 10 years. The percentage of CMV infections in the entire hospitalized lupus nephritis population was 5.3% (40/755). The principal clinical features of the 40 CMV-infected patients were hematological disorders (n = 25), fever (n = 21), liver dysfunction (n = 19), and respiratory symptoms (n = 12)...
February 17, 2017: Clinical and Experimental Medicine
https://www.readbyqxmd.com/read/28212922/organ-specific-biomarkers-in-lupus
#4
REVIEW
Haijing Wu, Jinrong Zeng, Ming Zhao, Qianjin Lu
Systemic lupus erythematosus (SLE) is a complex and highly heterogeneous disease, which affects multiple organs, including joints, skin, kidneys, heart, hematopoietic system, and nerve system. While the etiopathogenesis of SLE still remains unclear, genetic susceptibilities and aberrant epigenetic modifications are believed to be involved. For precision therapy, it is necessary to assess accurately and objectively organ involvements and disease activity, which is difficult by current clinical laboratory tests...
February 14, 2017: Autoimmunity Reviews
https://www.readbyqxmd.com/read/28191596/efficacy-and-safety-of-rituximab-in-comparison-with-common-induction-therapies-in-pediatric-active-lupus-nephritis
#5
Biswanath Basu, Birendranath Roy, Binu George Babu
BACKGROUND: Childhood-onset lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE). Despite treatment-related toxicities, cyclophosphamide (CYC) and glucocorticoid-based treatment protocols are still considered standard therapy in managing this multisystem disorder. An effective and safe alternative induction regimen is needed. METHODS: Forty-four pediatric patients with active LN aged 3.5-13.8 (median 8.4) years, of whom 32 entered the study at diagnosis of SLE, were followed over 36 months...
February 12, 2017: Pediatric Nephrology: Journal of the International Pediatric Nephrology Association
https://www.readbyqxmd.com/read/28185656/subacute-cutaneous-lupus-erythematosus-clinical-characteristics-disease-associations-treatments-and-outcomes-in-a-series-of-90%C3%A2-patients-at-mayo-clinic-1996-2011
#6
Dema T Alniemi, Albert Gutierrez, Lisa A Drage, David A Wetter
OBJECTIVE: To characterize the clinical presentation, laboratory studies, disease associations, and treatments of subacute cutaneous lupus erythematosus (SCLE). PATIENTS AND METHODS: A retrospective review of 90 patients with SCLE at Mayo Clinic from January 1, 1996, through October 28, 2011, was performed. RESULTS: The mean patient age at diagnosis was 61 years; 64 patients (71%) were women, and 11 cases (12%) were drug induced (1996-2000, no drug-induced cases; 2001-2005, 2 cases; 2006-2011, 9 cases)...
February 6, 2017: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/28157833/urinary-albumin-levels-are-independently-associated-with-renal-lesion-severity-in-patients-with-lupus-nephritis-and-little-or-no-proteinuria
#7
Jin Ding, Zhaohui Zheng, Xueyi Li, Yuan Feng, Nan Leng, Zhenbiao Wu, Ping Zhu
BACKGROUND Systemic lupus erythematosus (SLE) leads to renal lesions, which may be clinically silent in patients with little or no proteinuria. Early detection of these lesions may improve prognosis, but early markers are controversial. This study aimed to determine renal marker proteins associated with renal lesion severity in patients with lupus nephropathy (LN) and little or no proteinuria. MATERIAL AND METHODS Patients with LN and little or no proteinuria (<0.5 g/24 hours) (n=187) that underwent kidney biopsy were grouped according to: low severity (Class I or II; n=116) versus high severity (Class III, IV, or V; n=71)...
February 3, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/28147262/efficacy-of-belimumab-on-renal-outcomes-in-patients-with-systemic-lupus-erythematosus-a-systematic-review
#8
REVIEW
S Sciascia, M Radin, J Yazdany, R A Levy, D Roccatello, M Dall'Era, Maria J Cuadrado
Both BLISS-52 and BLISS-76 international phase III trials in Systemic Lupus Erythematosus (SLE) met their primary outcomes; however, they were not designed to assess the efficacy of belimumab for the treatment of lupus nephritis (LN). LN is a frequent cause of SLE-associated morbidity and mortality, and emerging evidence suggests a potential therapeutic role for agents that target B lymphocyte stimulator (BLyS). We conducted a systematic review to identify data on the effect of belimumab on LN. A total of 2004 patients with SLE were identified from 11 studies...
January 29, 2017: Autoimmunity Reviews
https://www.readbyqxmd.com/read/28143529/individualized-patient-decision-aid-for-immunosuppressive-drugs-in-women-with-lupus-nephritis-study-protocol-of-a-randomized-controlled-trial
#9
Jasvinder A Singh, Nipam Shah, Candace Green
BACKGROUND: Systemic Lupus erythematosus (SLE), also commonly referred to as lupus, is a rare, but sometimes, fatal disease, that primarily affects young women. Lupus nephritis, a common manifestation of lupus, is more common and more devastating in patients of minority race/ethnicity. Patients have negative views of immunosuppressive drugs for lupus nephritis due to a concern about side effects and under-appreciation of its benefit. We designed a study to assess the effectiveness of individualized, computerized patient decision-aid for immunosuppressive drugs for lupus nephritis compared to a standard pamphlet for patient decision-making...
January 31, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/28143420/papulonodular-mucinosis-guillain-barr%C3%A3-syndrome-and-nephrotic-syndrome-in-a-patient-with-systemic-lupus-erythematosus-a-case-report
#10
Xiaole Su, Xi Qiao, Jing Li, Lifang Gao, Chen Wang, Lihua Wang
BACKGROUND: Awareness of the spectrum of clinical manifestations of systemic lupus erythematosus (SLE), especially uncommon changes, is essential for diagnosis and effective management of patients. CASE PRESENTATION: A 26-year-old Chinese man with SLE initially manifested cutaneous papulonodular mucinosis and developed acute Guillain-Barré syndrome and class V lupus nephritis 2 years later. His cutaneous nodules had not been idententified for 2 years and were resected by surgical procedures twice until SLE was diagnosed...
February 1, 2017: BMC Nephrology
https://www.readbyqxmd.com/read/28133935/post-transplant-immune-complex-nephritis-in-a-patient-with-systemic-lupus-erythematosus-associated-with-anca-vasculitis
#11
Carlos Sanchez, Alejandra Rebolledo, Junior Gahona, Mauricio Rojas, Raquel Jiménez, Aurora Bojórquez
Nearly 20% of SLE corresponds to the pediatric population, and 75% of them have kidney involvement representing an important etiology of chronic kidney disease. A correlation between SLE and ANCA-associated vasculitis has been identified as an overlapping syndrome. Kidney allograft recurrence is rare in SLE when disease control is achieved and with nowadays immunosuppression treatment. Histologic transformation is unusual, especially when there are negative serologic markers and no immune complex deposition reported in native kidneys...
January 29, 2017: Pediatric Transplantation
https://www.readbyqxmd.com/read/28130617/prolactin-has-a-pathogenic-role-in-systemic-lupus-erythematosus
#12
Luis J Jara, Gabriela Medina, Miguel A Saavedra, Olga Vera-Lastra, Honorio Torres-Aguilar, Carmen Navarro, Monica Vazquez Del Mercado, Luis R Espinoza
Prolactin, a 23-kDa peptide hormone, is produced by the anterior pituitary gland and extrapituitary sites including the immune cells. Prolactin (PRL) participates in innate and adaptive immune response. PRL stimulates the immune cells by binding to receptor (PRL-R). Binding of PRL to its receptor activates the Janus kinase-signal transducer (JAK-STAT). Activation of these cascades results in endpoints such as immunoestimulator and immunosupressor action. Prolactin belongs to the network of immune-neuroendocrine interaction...
January 28, 2017: Immunologic Research
https://www.readbyqxmd.com/read/28121241/systemic-lupus-erythematosus-and-risk-of-preterm-birth-a-systematic-review-and-meta-analysis-of-observational-studies
#13
S Wei, K Lai, Z Yang, K Zeng
We performed a meta-analysis to identify the association between systemic lupus erythematosus (SLE) and preterm birth. In this study, we studied the effects of SLE, SLE disease activity, a history of nephritis and active nephritis on preterm birth. Searches were conducted before 20 May 2016 of PubMed, Embase, Medline and Cochrane Library of literature and article reference lists. Eleven observational case-control studies and thirteen cohort studies met the inclusion criteria. The pooled relative risk (RR) for the risk of preterm birth in SLE patients versus controls was 2...
January 1, 2017: Lupus
https://www.readbyqxmd.com/read/28120479/urinary-haptoglobin-alpha-1-anti-chymotrypsin-and-retinol-binding-protein-identified-by-proteomics-as-potential-biomarkers-for-lupus-nephritis
#14
Amita Aggarwal, Ranjan Gupta, V S Negi, Liza Rajasekhar, Ramnath Misra, Padam Singh, Vinita Chaturvedi, Sudhir Sinha
OBJECTIVE: Identification by proteomics and validation by ELISA of potential urinary biomarkers for lupus nephritis. METHODS: Study subjects comprised 88 systemic lupus erythematosus (SLE) patients and 60 controls (rheumatoid arthritis, diabetes mellitus and healthy individuals). Based on SLE disease activity index (SLEDAI) patients were classified as active renal (AR), active non-renal (ANR) or inactive disease (ID).Urinary proteins from a group of patients with AR or ID were resolved by two-dimensional gel electrophoresis and identified by MALDI-TOF-MS/MS...
January 24, 2017: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/28118527/from-childhood-to-adulthood-the-trajectory-of-damage-in-patients-with-childhood-onset-systemic-lupus-erythematosus
#15
Lily Sh Lim, Eleanor Pullenayegum, Lillian Lim, Dafna Gladman, Brian Feldman, Earl Silverman
Objectives 1) To determine the longitudinal damage trajectory of patients with childhood-onset SLE (cSLE). 2) To identify baseline and disease course predictors of damage trajectory. Methods This is a retrospective inception cohort. Longitudinal pediatric-age data was obtained from a cSLE research database while adult-age data was obtained from either a research database or patients' charts. Baseline factors were tested as predictors. Time-varying factors were lagged 6 to 24 months before a visit for testing their predictive effects...
January 24, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28116572/uch-l1-expressed-by-podocytes-a-potentially-therapeutic-target-for-lupus-nephritis
#16
Ji-Hong Cui, Xin Xie
Systemic lupus erythematosus (SLE) is a multisystem disease affecting many organs, and the most severe complication is lupus nephritis. Podocyte injury and loss play vital roles in the pathogenesis of lupus nephritis. Studies have shown that ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) is involved in the pathogenesis and progression of many diseases, such as neurodegenerative disorders, cancers, and diabetes. Recently, numerous studies have indicated that UCH-L1 was upregulated in the podocytes in immune complex-mediated glomerulonephritis...
January 23, 2017: Inflammation
https://www.readbyqxmd.com/read/28097391/-tapering-and-termination-of-immunosuppressive-therapy-systemic-lupus-erythematosus
#17
REVIEW
M Aringer, N Leuchten, R Fischer-Betz
Similar to patients with other rheumatic diseases, patients with systemic lupus erythematosus (SLE) nowadays can also have the desire to terminate immunosuppressive and immunomodulatory medications. In order to provide appropriate advice to patients, the two main issues are the risk of severe adverse events under long-term therapy with any drug and the perceived risk of a flare, in particular of severe flares. The risks of long-term therapy vary greatly between drugs, ranging from severe unacceptable risks with cyclophosphamide and higher dose glucocorticoids to low risks usually outweighed by long-term benefits with hydroxychloroquine...
February 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28063160/elevated-semaphorin5a-in-systemic-lupus-erythematosus-is-in-association-with-disease-activity-and-lupus-nephritis
#18
Yan Du, Xinyu Wu, Mo Chen, Wenwen Wang, Weihong Xv, Lv Ye, Di Wu, Jing Xue, Wenjia Sun, Judong Luo, Huaxiang Wu
OBJECTIVE: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by extensive immune response including over-activation of T and B cells development of pathogenic autoantibodies, organ damage induced by the formation and deposition of immune complex, and the abnormal elevation of type I interferon. Semaphorin5A (Sema5A), is essentially involved in immune cell regulation and also implicated in the pathogenesis of autoimmune disorders. We aimed to evaluate the role of Sema5A in patients with SLE...
January 7, 2017: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/28059023/the-short-term-efficacy-of-bortezomib-combined-with-glucocorticoids-for-the-treatment-of-refractory-lupus-nephritis
#19
H Zhang, Z Liu, L Huang, J Hou, M Zhou, X Huang, W Hu, Z Liu
Objective The treatment of refractory lupus nephritis (LN) remains challenging for clinicians because these patients either do not respond to conventional therapy or relapse during the maintenance treatment period. The aim of this study was to investigate the efficacy and safety of bortezomib combined with glucocorticoids in refractory lupus patients. Methodology Five refractory LN patients aged 21 to 43 years (four females and one male) with biopsy-proven diagnosis (four with type IV and one with type V+IV) were recruited...
January 1, 2017: Lupus
https://www.readbyqxmd.com/read/28059021/interferon-regulatory-factor-5-gene-polymorphism-in-egyptian-children-with-systemic-lupus-erythematosus
#20
A Hammad, Y M Mossad, N Nasef, R Eid
Background Increased expression of interferon-inducible genes is implicated in the pathogenesis of systemic lupus erythematosus (SLE). Interferon regulatory factor 5 (IRF5) is one of the transcription factors regulating interferon and was proved to be implicated in the pathogenesis of SLE in different populations. Objectives The objective of this study was to investigate the correlation between polymorphisms of the IRF5 gene and SLE susceptibility in a cohort of Egyptian children and to investigate their association with clinico-pathological features, especially lupus nephritis...
January 1, 2017: Lupus
keyword
keyword
74828
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"